Sanofi launches 2 diabetes drugs

Hyderabad: Drug maker Sanofi-Synthelabo (India) Private Limited on Tuesday launched two drugs Lyxumia and Zemiglo for type 2 diabetes patients. While Lyxumia is a once daily, non-insulin injectable drug, Zemiglo is a once daily, oral tablet. India is home to the second largest number of adults living with diabetes worldwide, after China, with 69.1 million patients and expected to rise to 1401 million in 2040, the company said in a statement, citing the International Diabetes Federation Diabetes Atlas 2015. India is the largest contributor to South East Asia regional mortality, with 1 million deaths attributable to diabetes.

“The challenge people living with diabetes face today is to keep their glucose levels under control, nearly 50 per cent of people living with diabetes remain uncontrolled. Sanofi India is proud of its strong legacy in diabetes management,” said N Rajaram, Country Head & General Manager, Pharmaceutical Operations, Sanofi India.

The launch of two additions to Sanofi India portfolio is our step forward in developing new solutions for people with type 2 diabetes. It is also a testament to Sanofi India’s commitment to help to address the current treatment gaps in our country.